TYLENOL COLD MULTI-SYMPTOM SEVERE OTC
Generic Name and Formulations:
Acetaminophen 325mg, dextromethorphan HBr 10mg, guaifenesin 200mg, phenylephrine HCl 5mg; per Cool Burst caplet; contains sodium 3mg/caplet.
McNeil Consumer Healthcare
Indications for TYLENOL COLD MULTI-SYMPTOM SEVERE:
Nasal congestion, nonproductive cough, sore throat, headache, fever, minor aches and pains.
Swallow whole. 2 caplets every 4 hours; max 12 caplets/24 hours.
During or within 14 days of MAOIs. Concomitant other acetaminophen products.
Hepatic dysfunction. Cardiovascular disease. Hypertension. GI or GU obstruction. Thyroid disease. Diabetes. Asthma. Lower respiratory disorders. Pregnancy. Nursing mothers.
See Contraindications. Hypertensive crisis with MAOIs. Increased risk of hepatotoxicity with ≥3 alcoholic drinks/day. β-blockers increase pressor effects of sympathomimetics. Antihypertensives antagonized.
Analgesic + antitussive + expectorant + sympathomimetic.
Nervousness, dizziness, insomnia, hepatotoxicity (overdosage).
Neurology Advisor Articles
- Clarifying Cardiovascular Risk in Migraine
- Parkinson Disease Symptom Fluctuations Well-Managed With Adaptive Deep Brain Stimulation
- More Evidence Supports Benefits of Cannabidiol for Treatment-Resistant Epilepsy
- Monthly Erenumab Reduces Frequency of Episodic Migraine
- Reduced Risk for Multiple Sclerosis Linked to Greater Sun Exposure
- Tamsulosin Associated With Dementia Risk in Older Patients With BPH
- FDA Approves Blood Test to Assess Concussion
- Gait Difficulty in Parkinson Disease May Be Associated With More Progressive Disease Course
- Tau PET a Useful Biomarker for Alzheimer Disease Risk and Progression
- Multiple Sclerosis Drug Zinbryta Withdrawn From the Market
- Incidence of Delayed Traumatic Intracranial Hemorrhage Low in Older Adults With Blunt Head Trauma
- Older Epilepsy Patients More Likely to Experience AED, Non-AED Drug Interaction
- Female Gender, Natalizumab Exposure Associated With Increased Lymphopenia Risk in FNG-Treated MS
- Accelerated Cognitive Decline Associated With Retinopathy
- Treatment Effects Often Exaggerated in Early Clinical Studies